GlassScriptPhysician profile
Kevin Lee Pressley
NPI 1396854956
$1,582.27
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $297 · 2021: $455 · 2022: $479 · 2023: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317.07 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $245.11 | 2019-2023 | |
| Lilly USA, LLC | $201.41 | 2020-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $156.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.07 | 2019-2023 | Jardiance |
| Abbott Laboratories | $111.62 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $108.10 | 2021-2023 | |
| Glaxosmithkline, LLC. | $71.64 | 2021-2022 | |
| Pfizer INC. | $57.36 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $52.63 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $33.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.93 | 2022-2023 | Givlaari |
| Janssen Pharmaceuticals, INC | $21.14 | 2021 | |
| Astellas Pharma US INC | $18.35 | 2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $16.12 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicure Pharma INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Pressley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.